Pancreatin
drugOn this page
Also known as CombizymCotazymCreonCreon 10000Creon 25000Creon 40000Creon microEurobiol 25000Kreon for kinderNutrizymNutrizym 10Nutrizym 22Nutrizym grPancrease hlPancrex vPancrex v 125Pancrex v ftePankreon 700Panzytrat 10000
Summary
Pancreatin (CHEMBL2108073) is a phase-3 clinical-stage unknown.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Clinical trials: 21
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108073 |
| Name | Pancreatin |
| Type | Unknown |
| Max phase | 3 |
Also known as: Combizym, Cotazym, Creon, Creon 10000, Creon 25000, Creon 40000, Creon micro, Eurobiol 25000, Kreon for kinder, Nutrizym, Nutrizym 10, Nutrizym 22
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 21.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 11 |
| PHASE3 | 3 |
| Not specified | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06099119 | PHASE4 | RECRUITING | Efficacy of PERT for PEI in Unresectable Pancreatic Cancer. |
| NCT07557394 | PHASE4 | NOT_YET_RECRUITING | A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui Tongbian Capsules Combined With Pancreatin Enteric-coated Capsules on Pancreatic Exocrine Function in Patients After Curative Resection for Pancreatic Cancer |
| NCT00160186 | PHASE4 | COMPLETED | Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy |
| NCT00535756 | PHASE4 | COMPLETED | Creon After Pancreatic Surgery |
| NCT00957151 | PHASE4 | COMPLETED | Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis |
| NCT01865695 | PHASE4 | TERMINATED | Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase |
| NCT02009410 | PHASE4 | WITHDRAWN | A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 |
| NCT02097394 | PHASE4 | UNKNOWN | The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps |
| NCT04315311 | PHASE4 | WITHDRAWN | Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer |
| NCT05069597 | PHASE4 | COMPLETED | Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon |
| NCT06119880 | PHASE4 | UNKNOWN | The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy |
| NCT00623025 | PHASE3 | TERMINATED | Creon in HIV Patients With Steatorrhea |
| NCT00705978 | PHASE3 | COMPLETED | Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis |
| NCT01012908 | PHASE2/PHASE3 | UNKNOWN | Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency |
| NCT01747330 | PHASE3 | COMPLETED | Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency |
| NCT07450547 | PHASE2 | RECRUITING | Phase 2 Study to Assess the Safety and Efficacy of ANG003 |
| NCT02733848 | PHASE1 | TERMINATED | CREON for the Treatment of Post-RYGB Hypoglycemia |
| NCT05266963 | EARLY_PHASE1 | COMPLETED | Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes |
| NCT01154608 | Not specified | COMPLETED | Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis |
| NCT01652157 | Not specified | TERMINATED | Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy) |
| NCT04949828 | Not specified | COMPLETED | Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.